Clinical Trial Update: Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse [Phase 4]

View source ↗

Summary

A Phase 4 study comparing 625 mg versus 1250 mg of oral methylprednisolone for relapse in multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Methylprednisolone (oral) (methylprednisolone)

Snippet

Sponsor: Germans Trias i Pujol Hospital | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED